



Press release

Innovative plant-based bioproduction company, Samabriva, announces the appointment of a new member of the Board.

Amiens (France), July 9th 2024 — Samabriva, a biotechnology company specializing in bioproduction of high value molecules, is delighted to announce that Florence Vicaire has been appointed to the Board of Directors.

Florence has more than 25 years of leadership experience in business development , including strategy development and execution in the bioproduction sector. She has held positions as global business leader at GE Healthcare and Cytiva and worked in Europe, Asia and North America. Currently Florence serves as the Chief Commercial Officer (CCO) of Univercells Technologies, a position she assumed since 2022.

Marina Guillet, CEO and Pascal Lizin, Chairman of the Board of Samabriva commented: *“Florence is an ideal Board member for Samabriva, who complete the current composition of the board. Her extensive business development background will help Samabriva strengthen its channel partnerships, develop strategic alliances and expand our international sales presence. We believe her vast expertise will help guide Samabriva as we expand.”*

Commenting on his appointment, Florence Vicaire said *“I am thrilled to join the Board of Directors at Samabriva, a company at the forefront of plant-based bioproduction. Samabriva’s approach to producing cost effective and sustainable high value molecules for pharmaceuticals and cosmetics aligns perfectly with the evolving needs of these industries. I look forward to sharing my experience in bioproduction and business development to support Samabriva's growth strategy as it expands its market presence.”*

About Samabriva: Samabriva is a plant-based biotechnology company that has successfully developed a proprietary bioproduction platform available to companies looking for affordable production of high-value molecules using large scale bioreactors.

The platform combines the advantages of plant-based systems (low cost, safe, serum- and animal-free) with traditional bioproduction in large-scale bioreactors to offer continuous, reliable and environmentally sustainable manufacture of a wide range of high value molecules all year round, in any location.

The manufacture of secondary metabolites currently lacks local scalable and sustainable production processes. Currently, secondary metabolites are mainly produced by growing plants in fields. However, extracting these compounds produces very small amounts from each plant. For example, 1 gram of vinblastine for chemotherapy treatment requires half a ton of dry leaves from the Madagascar periwinkle, *Catharanthus roseus* making the process costly and environmentally unsustainable.

The manufacture of recombinant proteins currently lacks cost effective and contaminant free production processes. Recombinant proteins are typically produced in bacterial (*Escherichia coli*) or more commonly in mammalian (typically Chinese Hamster Ovary (CHO)) cell cultures. These bioproduction systems are complex and costly. Mammalian cell cultures often use animal-derived media that require extensive purification of the final product to avoid any risk of virus or prion transmission.

The increasing demand for these high value molecules* is driving the need to produce them at scale in a more controlled and environmentally sustainable way.

Samabriva's innovative plant-based bioprocess platform uses *in vitro* hairy root culture to produce secondary metabolites and recombinant proteins at scale and with high yields.

Visit our website: www.samabriva.com

For further information please contact:

Marina Guillet, CEO, Samabriva - +33 (0) 322 092 830

Marina.guillet@samabriva.com

Notes:

*The global botanical and plant-derivative drug market is growing rapidly (at an estimated CAGR of 8.58% between 2018 and 2026¹) while the recombinant protein market is expected to grow even faster (at a CAGR of 11.2% between 2021-2026²).

1. Global botanical and plant derivative drug market forecast 2018-2026 ; Marker Research Report
2. <https://www.mordorintelligence.com/industry-reports/recombinant-proteinmarket#:~:text=market%20overview,forecast%20period%2c%202021%2d2026>. Recombinant protein market - growth, trends,covid-19 impact, and forecasts (2022 - 2027)- Mordor intelligence